Clinical Commander

Back to dossier
cardio.acute-hf.diabetic-cardiomyopathy.v1PRODUCTION
cardio.acute-hf.diabetic-cardiomyopathy.v1

Acute HF — diabetic cardiomyopathy

cardiologyacuteadult
Hard-required inputs
0 / 11
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

HF in diabetic patient without obstructive CAD / long-standing HTN / valvular cause → diabetic cardiomyopathy phenotype; phenotype-first triage drives SGLT2i-first treatment paradigm

Inputs
1
Actions
0
Advance rule
Set
Advance when

diabetic CMP framed

Patient inputs (13)

Long-duration diabetes is hallmark; older patients more often HFpEF phenotype; younger T1DM with diabetic CMP rare but possible

T2DM > T1DM prevalence; duration ≥10 yr typical; HbA1c trajectory drives pathophysiology severity (AGE accumulation, lipotoxicity)

Retinopathy + nephropathy + neuropathy cluster supports diabetic CMP diagnosis; absence makes alternative etiology more likely

Identify glitazones (must stop — fluid retention precipitates HF) and saxagliptin (HF signal SAVOR-TIMI 53); identify SGLT2i + GLP-1 RA already on board for continuation; insulin regimen for titration

Diabetic nephropathy frequently coexists; eGFR drives SGLT2i eligibility (start ≥20 mL/min per labels), GLP-1 RA dosing (semaglutide ok any eGFR), metformin (avoid if eGFR <30), and loop diuretic dose

Chronic glycemic control marker; target 7–8% (not strict <7 per ACCORD PMID 18539917); informs intensification urgency without overshooting

Diagnose HF + risk stratify; obesity may blunt levels (HFpEF caveat); trend with diuresis

Rule out acute MI as alternative explanation; persistent low-level elevation common in diabetic CMP from microvascular injury

Hyperglycemia may indicate DKA (T1DM) or HHS (T2DM) superimposed on ADHF — life-threatening combined emergency

LVEF + diastolic function (E/e′) + LV mass + GLS (impaired GLS earliest sign of diabetic CMP); rule out valvular disease and segmental wall motion (CAD)

BP affects ARNI/ACEi initiation; volume status; SGLT2i can lower BP modestly (5 mmHg) — start with caution if SBP <100

Diffuse subendocardial LGE + T1/ECV mapping confirms diffuse interstitial fibrosis pattern of diabetic CMP; excludes ischemic + amyloid + sarcoid mimics

Rubidium or NH3 PET myocardial flow reserve <2.0 confirms microvascular dysfunction even with normal coronary angiogram — supports diabetic CMP diagnosis

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateninghyperglycemic_crisis_overlapping_adhf
    DKA (T1DM) or HHS (T2DM) superimposed on ADHF — combined cardiogenic + osmotic emergency
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereglitazone_exposure_error_in_hf
    Pioglitazone or rosiglitazone prescribed in patient with HF (transferred from other facility or continued from outpatient regimen)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveresaxagliptin_exposure_error_in_hf
    Saxagliptin prescribed in patient with HF — SAVOR-TIMI 53 (Scirica NEJM 2013 PMID 23992602) HF hospitalization signal
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatesemaglutide_eligibility_for_obese_hfpef
    HFpEF + BMI ≥30 + diabetic — STEP-HFpEF eligibility for semaglutide 2.4 mg weekly (KCCQ + 6MWD improvement, weight loss 5%+)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatemicrovascular_ischemia_confirmed_on_pet
    Cardiac PET myocardial flow reserve <2.0 with normal coronary angiogram in diabetic patient — confirms microvascular dysfunction supporting diabetic CMP
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Diabetic cardiomyopathy ADHF — SGLT2i-first regimen (EMPULSE PMID 35347356 + ACC/AHA 2022 HF + ADA 2024)
axis: diabetic_cardiomyopathy_sglt2_first
Selected axis "Diabetic cardiomyopathy ADHF — SGLT2i-first regimen (EMPULSE PMID 35347356 + ACC/AHA 2022 HF + ADA 2024)" by default fallback (first axis)
  • empagliflozin
    first line
    sglt2_inhibitor
    10 mg PO daily from day 1 of admission • PO • daily lifelong
    triggers: adhf_in_diabetic_cmp, hfpef_or_hfref, egfr_at_least_20
    EMPULSE (Voors Nat Med 2022 PMID 35347356) — in-hospital initiation safe + 36% improvement in primary clinical benefit hierarchy at 90 d in HFrEF + HFpEF, diabetic + non-diabetic; EMPEROR-Reduced PMID 32865377; EMPEROR-Preserved PMID 34449189
    rxcui 1545653
  • dapagliflozin
    first line
    sglt2_inhibitor
    10 mg PO daily • PO • daily lifelong
    triggers: adhf_in_diabetic_cmp, alternative_to_empagliflozin, egfr_at_least_25
    DAPA-HF (McMurray NEJM 2019 PMID 31535829) HFrEF; DELIVER (Solomon NEJM 2022 PMID 36027570) HFpEF; class effect demonstrated
    rxcui 1488564
  • semaglutide
    add on
    glp1_receptor_agonist
    0.25 mg SC weekly × 4 wk → titrate to 2.4 mg weekly (HFpEF + obesity) or 1 mg weekly (T2DM) • SC • weekly
    triggers: hfpef_with_obesity_bmi_at_least_30, inadequate_glycemic_control_on_metformin_sglt2i
    STEP-HFpEF (Kosiborod NEJM 2023 PMID 37877559) — semaglutide 2.4 mg weekly in obese HFpEF: 5%+ weight loss, KCCQ + 6MWD improvement; SELECT cardiovascular benefit independent of T2DM
    rxcui 1991302
  • metformin
    comorbidity specific
    biguanide
    500 mg PO BID, titrate to 1000 mg BID • PO • BID
    triggers: t2dm_egfr_at_least_30, hold_during_acute_decompensation_due_to_lactic_acidosis_risk
    ADA 2024 first-line oral; HOLD during acute illness (lactic acidosis risk); restart when stable + eGFR ≥30
    rxcui 6809
  • insulin glargine
    comorbidity specific
    long_acting_basal_insulin
    0.2–0.3 U/kg SC daily basal + correctional regular insulin scale • SC • daily basal
    triggers: hyperglycemia_during_admission, insulin_naive_or_continuing_outpatient_basal
    Basal-bolus regimen for inpatient hyperglycemia; target 140–180 mg/dL per ADA inpatient; avoid sliding-scale-only
    rxcui 274783
  • furosemide
    first line
    loop_diuretic
    40 mg IV (or 2.5x outpatient dose for chronic users — DOSE-AHF PMID 21366472) • IV/PO • q12h titrate to UOP 100–200 mL/h
    triggers: volume_overload_adhf
    Standard ADHF decongestion; DOSE-AHF — high-dose strategy improves dyspnea more than low; transition to PO when stable
    rxcui 4603
  • sacubitril-valsartan
    first line
    arni_arb_neprilysin_inhibitor
    24/26 mg PO BID titrate to 97/103 mg BID • PO • BID
    triggers: hfref_with_lvef_below_40, sbp_at_least_100, no_recent_acei_in_36h
    PIONEER-HF (Velazquez NEJM 2019 PMID 30403955) — in-hospital initiation safe + reduces NT-proBNP more than enalapril; ACC/AHA 2022 HF Class I in HFrEF
    rxcui 1656328

outpatient playbook — drug actions (3)

  1. 1. continue SGLT2i lifelong
    rxcui 1545653
    empagliflozin 10 mg PO daily • PO • daily
    trigger: maintenance
    EMPEROR-Reduced/Preserved sustained benefit
  2. 2. continue GLP-1 RA if HFpEF + obese
    rxcui 1991302
    semaglutide 2.4 mg SC weekly • SC • weekly
    trigger: maintenance HFpEF + obesity
    STEP-HFpEF PMID 37877559 + SELECT CV benefit
  3. 3. continue GDMT if HFrEF
    rxcui 1656328
    sacubitril-valsartan 97/103 BID + carvedilol max + spironolactone 25 + SGLT2i • PO • as scheduled
    trigger: HFrEF maintenance
    ACC/AHA 2022 HF Class I 4-pillar

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Dyspnea / orthopnea / edema in T2DM ≥10 yr without obstructive CAD or long-standing HTN → diabetic cardiomyopathy pathway; NT-proBNP elevated + HbA1c >9% + concurrent diabetic microvascular complications (retinopathy/nephropathy/neuropathy); Echo Grade II/III diastolic dysfunction + LVH + impaired GLS (global longitudinal strain) in diabetic patient — early diabetic cardiomyopathy.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Acute HF — diabetic cardiomyopathy** (cardio.acute-hf.diabetic-cardiomyopathy.v1).
Phenotype framing: Diabetic CMP vs ischemic CMP (CAD on angio) vs hypertensive CMP (long HTN history) vs amyloidosis (thick walls, low voltage, apical sparing) vs HFpEF without specific etiology
Scope: HF in diabetic patient without obstructive CAD / long-standing HTN / valvular cause → diabetic cardiomyopathy phenotype; phenotype-first triage drives SGLT2i-first treatment paradigm

No severity triggers fired against current inputs.

Plan

Regimen axis: **Diabetic cardiomyopathy ADHF — SGLT2i-first regimen (EMPULSE PMID 35347356 + ACC/AHA 2022 HF + ADA 2024)**.
1. empagliflozin 10 mg PO daily from day 1 of admission PO daily lifelong (sglt2_inhibitor, first line) — EMPULSE (Voors Nat Med 2022 PMID 35347356) — in-hospital initiation safe + 36% improvement in primary clinical benefit hierarchy at 90 d in HFrEF + HFpEF, diabetic + non-diabetic; EMPEROR-Reduced PMID 32865377; EMPEROR-Preserved PMID 34449189
2. dapagliflozin 10 mg PO daily PO daily lifelong (sglt2_inhibitor, first line) — DAPA-HF (McMurray NEJM 2019 PMID 31535829) HFrEF; DELIVER (Solomon NEJM 2022 PMID 36027570) HFpEF; class effect demonstrated
3. semaglutide 0.25 mg SC weekly × 4 wk → titrate to 2.4 mg weekly (HFpEF + obesity) or 1 mg weekly (T2DM) SC weekly (glp1_receptor_agonist, add on) — STEP-HFpEF (Kosiborod NEJM 2023 PMID 37877559) — semaglutide 2.4 mg weekly in obese HFpEF: 5%+ weight loss, KCCQ + 6MWD improvement; SELECT cardiovascular benefit independent of T2DM
4. metformin 500 mg PO BID, titrate to 1000 mg BID PO BID (biguanide, comorbidity specific) — ADA 2024 first-line oral; HOLD during acute illness (lactic acidosis risk); restart when stable + eGFR ≥30
5. insulin glargine 0.2–0.3 U/kg SC daily basal + correctional regular insulin scale SC daily basal (long_acting_basal_insulin, comorbidity specific) — Basal-bolus regimen for inpatient hyperglycemia; target 140–180 mg/dL per ADA inpatient; avoid sliding-scale-only
6. furosemide 40 mg IV (or 2.5x outpatient dose for chronic users — DOSE-AHF PMID 21366472) IV/PO q12h titrate to UOP 100–200 mL/h (loop_diuretic, first line) — Standard ADHF decongestion; DOSE-AHF — high-dose strategy improves dyspnea more than low; transition to PO when stable
7. sacubitril-valsartan 24/26 mg PO BID titrate to 97/103 mg BID PO BID (arni_arb_neprilysin_inhibitor, first line) — PIONEER-HF (Velazquez NEJM 2019 PMID 30403955) — in-hospital initiation safe + reduces NT-proBNP more than enalapril; ACC/AHA 2022 HF Class I in HFrEF

Setting playbook (outpatient) — Long-term cardio-endocrine co-management: HbA1c 7–8% target, SGLT2i + GLP-1 RA + metformin foundation, GDMT 4-pillar maintenance, microvascular complication surveillance, advanced HF/transplant eval if progression
8. continue SGLT2i lifelong empagliflozin 10 mg PO daily PO daily — maintenance (EMPEROR-Reduced/Preserved sustained benefit)
9. continue GLP-1 RA if HFpEF + obese semaglutide 2.4 mg SC weekly SC weekly — maintenance HFpEF + obesity (STEP-HFpEF PMID 37877559 + SELECT CV benefit)
10. continue GDMT if HFrEF sacubitril-valsartan 97/103 BID + carvedilol max + spironolactone 25 + SGLT2i PO as scheduled — HFrEF maintenance (ACC/AHA 2022 HF Class I 4-pillar)

Non-pharmacologic actions:
- Lifestyle: weight loss, exercise, dietary counseling
- Smoking cessation
- Vaccinations (flu, pneumonia, COVID, RSV)
- Annual microvascular surveillance

AVOID / contraindication checks:
- Glitazone_pioglitazone_rosiglitazone_avoid_in_hf (fluid retention precipitates HF — ACC/AHA Class III)
- Saxagliptin_avoid_in_hf (HF hospitalization signal SAVOR TIMI 53 PMID 23992602)
- Metformin_hold_during_acute_decompensation (lactic acidosis risk; restart when eGFR ≥30 + stable)
- Sulfonylurea_caution_hypoglycemia_in_adhf (avoid glyburide; glipizide acceptable if needed)
- Sglt2i_hold_for_perioperative_3d_and_during_acute_illness_for_euglycemic_dka_risk (FDA label)
- Insulin_avoid_strict_glycemic_control_below_140 (inpatient hypoglycemia harm; ADA 140–180 mg/dL target)

Monitoring

Regimen monitoring:
- daily finger stick glucose q4 6h
- hba1c at 3 months target 7 8 percent not strict below 7
- sglt2i side effect screen uti mycotic infection euglycemic dka
- glp1 ra nausea pancreatitis screen
- bmp q24 48h during diuresis for aki and hypokalemia

Setting (outpatient) monitoring:
- Quarterly + annual full restage

Follow-up plan: Cardiology + endocrinology co-clinic; STRONG-HF–style up-titration weekly × 4; HbA1c at 3 mo; ophthalmology + nephrology follow-up; semaglutide initiation if HFpEF + obesity; CGM consideration
- Close-out criterion: follow-up + chronic engine handoff scheduled

Monitoring phase: Daily weight + UOP + BMP; finger-stick glucose q4–6h; HbA1c trajectory; SGLT2i side-effect surveillance (UTI, mycotic infection, euglycemic DKA); GLP-1 RA tolerance (nausea); diuretic-induced AKI surveillance

Disposition

Current setting: outpatient — Long-term cardio-endocrine co-management: HbA1c 7–8% target, SGLT2i + GLP-1 RA + metformin foundation, GDMT 4-pillar maintenance, microvascular complication surveillance, advanced HF/transplant eval if progression

Disposition criteria:
- Long-term cardio-endocrine continuation; cross-link to cardio.hfref.core.v1 / cardio.hfpef.core.v1 / endo.dm2.core.v1

Escalation triggers (move to higher acuity):
- Progressive HF on max GDMT → advanced HF / transplant eval
- Worsening renal function → reassess SGLT2i + ARNI
- New microvascular event → intensify glucose + BP control

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] DKA (T1DM) or HHS (T2DM) superimposed on ADHF — combined cardiogenic + osmotic emergency
- [SEVERE] Pioglitazone or rosiglitazone prescribed in patient with HF (transferred from other facility or continued from outpatient regimen)
- [SEVERE] Saxagliptin prescribed in patient with HF — SAVOR-TIMI 53 (Scirica NEJM 2013 PMID 23992602) HF hospitalization signal

Citations

- 2022 ACC/AHA HF Guideline (Heidenreich) + ADA 2024 Standards + EMPULSE + DAPA-HF + STEP-HFpEF + SAVOR-TIMI 53 [PMID:35363499](https://pubmed.ncbi.nlm.nih.gov/35363499/)
- Cited evidence (PMID 35347356) [PMID:35347356](https://pubmed.ncbi.nlm.nih.gov/35347356/)
- Cited evidence (PMID 31535829) [PMID:31535829](https://pubmed.ncbi.nlm.nih.gov/31535829/)
- Cited evidence (PMID 32865377) [PMID:32865377](https://pubmed.ncbi.nlm.nih.gov/32865377/)
- Cited evidence (PMID 34449189) [PMID:34449189](https://pubmed.ncbi.nlm.nih.gov/34449189/)

Last reconciled with current guidelines: 2026-05-15.
References